Abstract
Abstract This chapter discusses abnormal fat distribution (lipodystrophy) associated with HIV and antiretroviral therapy by describing what is currently know about HIV-associated lipodystrophy, the current clinical implications of lipodystrophy in persons with HIV, and the therapeutic interventions that can be used to treat and improve the health status of persons with HIV and lipodystrophy. The learner will also understand the different manifestations of lipodystrophy, including fat loss (lipoatrophy), fat gain (lipohypertrophy), or mixed patterns and the associated increased risk of developing dyslipidemia, insulin resistance, diabetes mellitus, cardiovascular disease, fatty liver disease, renal disease, and metabolic syndrome. Associated treatments are also discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
